Specifications tableSubject areaBiologyMore specific subject areaFuchs endothelial corneal dystrophyType of dataText (FASTQ sequence files), tableHow data was acquiredHigh-throughput RNA sequencing using Illumina HiSeq 2500 Sequencing SystemData formatRawExperimental factorsSamples of corneal endothelium were obtained from patients with FECD during the endothelial keratoplasty. Control samples of corneal endothelium were collected from donors of the eye bank. Blood samples and iris tissues were also obtained for genotyping from patients and donors respectively.Experimental featuresTotal RNA was isolated from samples of corneal endothelium. After removing traces of DNA and ribosomal RNA whole transcriptome libraries were constructed and sequenced. Genotyping for CTG18.1 trinucleotide repeat expansion was performed using short tandem repeat (STR) and triplet primed PCR (TP-PCR) techniques.Data source locationMoscow, RussiaData accessibilityRaw data was deposited at NCBI SRA database under accession No. PRJNA524323 <https://www.ncbi.nlm.nih.gov/sra/PRJNA524323>Related research articleL.O. Skorodumova, A. V. Belodedova, O.P. Antonova, E.I. Sharova, T.A. Akopian, O. V. Selezneva, E.S. Kostryukova, B.E. Malyugin. CTG18.1 Expansion is the Best Classifier of Late-Onset Fuchs\' Corneal Dystrophy Among 10 Biomarkers in a Cohort From the European Part of Russia. Investig. Ophthalmology Vis. Sci. 59 (2018) 4748 [@bib1]**Value of the Data**•The dataset represents transcriptomes of samples from FECD patients as well as from control donors which can be compared to reveal molecular pathways altered in corresponding endothelial cells leading to their accelerated death.•The identification of affected metabolic and signaling pathways may indicate the direction of research for the development of specific non-surgical treatment of FECD.•All subjects in this study have already been genotyped for CTG18.1 expansion. The dataset includes samples from patients both with and without the expansion, which can be valuable for identifying the role this genetic variation plays in FECD pathogenesis.•Expression profiles are available in the form of raw sequencing reads that can be further processed by researchers using their own bioinformatic algorithms and analyzed together with their own data.

1. Data {#sec1}
=======

The dataset contains raw sequencing data obtained through the transcriptome sequencing of corneal endothelium from 12 patients with FECD and 6 donors. The data files (reads in FASTQ format) were deposited at NCBI SRA database under project accession No. PRJNA524323. Information about tissue samples collected from patients with FECD and control samples from donors is presented in [Table 1](#tbl1){ref-type="table"} and [Table 2](#tbl2){ref-type="table"}, respectively.Table 1Samples of corneal endothelium obtained from patients with FECD.Table 1Sample IDAge, yearsSexDiagnosisFECD stageComorbidityCEC (corneal endothelial cell) densityTime between cataract surgery and endothelial keratoplastyDfu_20170fОD FECDstage IIComplicated cataract[a](#tbl1fna){ref-type="table-fn"}568simultaneousDfu_20263mОD FECDstage IIComplicated cataract478simultaneousDfu_20357fOS FECDstage IIComplicated cataract463simultaneousDfu_20564fOS FECDstage IIComplicated cataract463simultaneousDfu_20779fOS FECDstage IIComplicated cataract486simultaneousDfu_20956fОD FECDstage IVNeovascularization, Pseudophakia--22 monthsDfu_21064mОD FECDstage IIComplicated cataract489simultaneousDfu_21272fOS FECDstage IIIPseudophakia50113 monthsDfu_21374mOS FECDstage IIComplicated cataract465simultaneousDfu_21570fОD FECDstage IIComplicated cataract464simultaneousDfu_21757fОD FECDstage IIIComplicated cataract503simultaneousDfu_21969fOS FECDstage IIComplicated cataract512simultaneous[^1]Table 2Control samples of corneal endothelium obtained from donors.Table 2Sample IDAge, yearsSexCause of deathCEC densityС_20147fCardiomyopathy2976C_20363mAsphyxia2864C_20554fAcute cardiovascular insufficiency2924C_20665fAcute cardiovascular insufficiency2931C_20764fAcute cardiovascular insufficiency2789C_20861mAcute cardiovascular insufficiency2812

All patients and donors were also characterized by genotyping for trinucleotide repeat polymorphism CTG18.1 in the TCF4 gene ([Table 3](#tbl3){ref-type="table"}).Table 3The data on genotyping patients with FECD and donors for CTG18.1 expansion.Table 3Sample IDSample groupTCF4 expansion statusNumber of expanded TCF4 allelesNumber of repeats in smaller TCF4 alleleNumber of repeats in larger TCF4 alleleDfu_201FECDexpanded112156Dfu_202FECDexpanded27272Dfu_203FECDexpanded27272Dfu_205FECDexpanded132127Dfu_207FECDexpanded11187Dfu_209FECDnon-expanded01114Dfu_210FECDnon-expanded01114Dfu_212FECDexpanded11444Dfu_213FECDexpanded114104Dfu_215FECDexpanded121114Dfu_217FECDnon-expanded01417Dfu_219FECDnon-expanded01517C_201Controlnon-expanded01418C_203Controlnon-expanded01118C_205Controlnon-expanded01117C_206Controlnon-expanded01115C_207Controlnon-expanded01117C_208Controlnon-expanded01717

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Ethical statements {#sec2.1}
-----------------------

This study was approved by the Institutional Review Board of The S. Fyodorov Eye Microsurgery Federal State Institution and was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).

2.2. Collection of tissue and blood samples from FECD patients {#sec2.2}
--------------------------------------------------------------

Samples of corneal endothelium were obtained from patients diagnosed with FECD and undergoing corneal transplantation at The S. Fyodorov Eye Microsurgery Federal State Institution. All patients included in this study had signed an informed consent form. [Table 2](#tbl2){ref-type="table"} summarizes information about tissue samples collected from patients with FECD. Disease stage was identified according to the Volkov and Dronov classification as described in Ref. [@bib1].

During the endothelial keratoplasty procedure, circular descemetorhexis with a diameter of 7--8 mm was performed using a special hook to obtain samples of corneal endothelium/Descemet\'s membrane (CEC-DM) complex. RNA in CEC-DM complex was stabilized using RNAlater solution (ThermoFisher Scientific, USA) according to the manufacturer\'s instructions. Venous blood (4--6 mL) was collected from each patient into vacutainer tubes with EDTA (Becton Dickinson, USA). Blood samples were stored at −20 °C prior to DNA extraction.

2.3. Collection of control tissue samples from donors {#sec2.3}
-----------------------------------------------------

Control samples of corneal endothelium were collected at the Eye Bank of The S. Fyodorov Eye Microsurgery Federal State Institution. Donor samples were selected from those not suitable for corneal transplantation. Information about control tissue samples collected from donors is presented in [Table 3](#tbl3){ref-type="table"}.

The eyeball was stored for a maximum of 1 day before extraction of the corneoscleral disc which then was kept in a preservative medium for the period of up to 12 hours. The preservative medium contained: 25% of medium 199, 25% of F-10 medium, 45.3% of DMEM, 2% dextran, 2.7% chondroitin sulfate, gentamicin sulfate 0.00014%, amphotericin B 0.00015%. Afterward, the corneoscleral disc was placed in an artificial anterior chamber endothelial side up. Circular excision of CEC-DM complex 7--8 mm in diameter was performed using spatula and tweezers. After isolation, the donor CEC-DM complexes were immediately immersed in the RNAlater solution (ThermoFisher Scientific, USA). Iris samples were also collected from donors for the TCF4 repeats expansion genotyping.

2.4. CEC density measurement {#sec2.4}
----------------------------

The density of corneal endothelial cells was measured using Tomey EM-3000 Specular Microscope (Tomey, USA). The shooting method was non-contact, the measurement mode was manual/automatic, the shooting area was 0.25 mm × 0.54 mm with 7 capture points (central + 6 points on the periphery). The accuracy of corneal thickness measurement was ±10nm \". CEC density was evaluated if at least one of the capture points had enough transparency for the analysis.

2.5. DNA extraction {#sec2.5}
-------------------

DNA was isolated from thawed blood samples with Gentra Puregene Blood Kit (Qiagen, Germany) according to the manufacturer\'s protocol. DNA was resuspended in a low TE buffer to a final concentration of 10 ng/μl. DNA from iris samples was extracted using ZR Genomic DNA Tissue MiniPrep (Zymo Research, USA).

2.6. Genotyping {#sec2.6}
---------------

Identification of the number of CTG repeats within the CTG18.1 allele in the TCF4 gene was carried out using short tandem repeat (STR) and triplet primed PCR (TP-PCR) techniques exactly according to the procedure described in Ref. [@bib1]. The TCF4 allele was classified as expanded if the number of CTG repeats was ≥40 according to previously reported literature [@bib2], [@bib3].

2.7. RNA extraction {#sec2.7}
-------------------

Disruption and homogenization of tissue samples were performed with TissueRuptor II (Qiagen, Germany). The time of homogenization was 20 seconds. Total RNA was isolated using RNeasy Micro Kit (Qiagen) following the manufacturer\'s protocol. Traces of DNA were removed with TURBO DNA-free Kit (ThermoFisher Scientific). RNA concentration was assessed using the Qubit 2 instrument (Invitrogen, USA) with Qubit HS RNA Assay Kit (ThermoFisher Scientific, USA). The quality of total RNA expressed as RNA Integrity Number (RIN) was determined with Bioanalyzer 2100 instrument (Agilent, USA) using an Agilent RNA Pico 6000 Kit (Agilent, USA) [@bib4]. On average, the RIN value of 6.5 was obtained, which is typical for RNA samples isolated from tissues [@bib5].

2.8. Transcriptome library preparation and sequencing {#sec2.8}
-----------------------------------------------------

Ribosomal RNA was depleted using NebNext rRNA Depletion Kit (Human/Mouse/Rat) (New England Biolabs, USA). Transcriptome libraries were constructed with NEBNext Ultra II Directional Library Prep Kit for Illumina (New England Biolabs, USA) and Multiplex Oligos for Illumina (96 Indexes) (New England Biolabs, USA). The resulting paired-end libraries were sequenced on the Illumina HiSeq 2500 instrument with 2 × 125 cycles using HiSeq SBS Kit v4 (Illumina, USA).
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[^1]: The cataract was classified as complicated if the patient had any other concomitant eye disease, which was FECD for all patients from this sample group.
